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ARTICLE

Microglia drive APOE-dependent neurodegeneration
in a tauopathy mouse model
Yang Shi1, Melissa Manis1, Justin Long1, Kairuo Wang1, Patrick M. Sullivan2, Javier Remolina Serrano1, Rosa Hoyle1, and David M. Holtzman1

Chronic activation of brain innate immunity is a prominent feature of Alzheimer’s disease (AD) and primary tauopathies.
However, to what degree innate immunity contributes to neurodegeneration as compared with pathological protein-induced
neurotoxicity, and the requirement of a particular glial cell type in neurodegeneration, are still unclear. Here we demonstrate
that microglia-mediated damage, rather than pathological tau-induced direct neurotoxicity, is the leading force driving
neurodegeneration in a tauopathy mouse model. Importantly, the progression of ptau pathology is also driven by microglia. In
addition, we found that APOE, the strongest genetic risk factor for AD, regulates neurodegeneration predominantly by
modulating microglial activation, although a minor role of apoE in regulating ptau and insoluble tau formation independent of
its immunomodulatory function was also identified. Our results suggest that therapeutic strategies targeting microglia may
represent an effective approach to prevent disease progression in the setting of tauopathy.

Introduction
Alzheimer’s disease (AD) is characterized by two types of
pathologies: 1) misfolded, aggregated proteins (in particular, intraneuronal tau pathology) that are capable of inducing direct neurotoxicity; and 2) chronic activation of the
brain’s innate immune system that may induce neurodegeneration via various mechanisms, such as neuronal
phagoptosis by microglia, complement-mediated neuronal
damage, cytokine or reactive oxygen species–induced cell
toxicity, etc. (Shi and Holtzman, 2018). However, to what
degree innate immunity contributes to neurodegeneration
as compared with tau-induced cell-autonomous neurotoxicity is unknown. APOE, the strongest genetic risk factor for
late-onset AD, encodes apolipoprotein E (apoE), which by
itself is a potent immune modulator (Vitek et al., 2009; Zhu
et al., 2012; Gale et al., 2014; Krasemann et al., 2017; Shi
et al., 2017), implying a critical role of brain innate immunity in AD pathogenesis.
We recently reported that apoE strongly regulates neurodegeneration in the setting of a tauopathy (Shi et al., 2017).
The presence of apoE, particularly apoE4, significantly exacerbated neurodegeneration in P301S mice, whereas genetic
ablation of murine Apoe was strongly neuroprotective. These
effects are in part due to apoE impacting glial function, in
addition to its potential direct regulation of tau pathogenesis
(Shi et al., 2017). However, to what extent apoE regulates

neurodegeneration via its immunomodulatory function, and
which glial cell types are involved in this process, are still
elusive. While both microglia and astrocytes are immune
competent, accumulating genetic and functional evidence
suggests that microglia, the brain-resident professional immune cells, may play a major role in regulating innate
immunity-induced neurodegeneration (Leyns et al., 2017;
Pimenova et al., 2018). A recent study shows that apoE cellautonomously regulates microglial activation (Krasemann
et al., 2017). Apoe deletion from microglia prevented microglia from acquiring a neurodegenerative phenotype that was
required for neuronal cell death in a facial nerve axotomy
model. This highlights a role of microglia in neurodegeneration and suggests that apoE functioning through microglia constitutes an essential mechanism regulating
neurodegeneration, at least in an acute axotomy model. To
understand the role of microglia in neurodegeneration in
neurodegenerative diseases and how it is linked to apoE function, we depleted microglia in P301S tau transgenic mice that
are homozygous for human APOE4 (TE4) or with no expression
of Apoe (TEKO) from 6 to 9.5 mo of age, a critical time window
when neurodegeneration occurs in this mouse model. We
identified a critical role of microglia in driving both neurodegeneration and tau pathogenesis, as well as in mediating
apoE’s effect on neurodegeneration.
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Results
Chow formula and mouse sex affect microglial depletion
efficiency by PLX3397
To deplete microglia, we used PLX3397, a selective CSF1R/c-kit/
FLT3 inhibitor that has been shown to readily cross the blood
brain barrier and eliminate microglia via oral delivery in mouse
chow (Elmore et al., 2014). We initially formulated PLX3397 in a
grain-based chow (Purina 5053) that has been used for our
previous research. However, we found a strong chow- and sexdependent effect on the drug efficiency in depleting microglia.
PLX3397 supplemented in grain-based Purina 5053 showed a
significantly lower efficiency in depleting microglia compared
with PLX3397 supplemented in a purified ingredient chow (AIN76A) that has been used in previous PLX3397 research (Fig. S1, A
and B). Additionally, male mice showed a higher level of microglial reduction than females when treated with the same
chow (AIN-76A; Fig. S1, A and B). These effects appeared to be
caused by different levels of PLX3397 in the plasma, as plasma
PLX3397 levels strongly correlated with the degree of microglial
reduction in the brain (Fig. S1, C and D). We therefore selected
AIN-76A chow and used only male mice for the study. To
guarantee that we achieved complete microglial ablation, we
formulated the chow with a higher concentration of PLX3397
(400 mg/kg) as compared with the previously reported concentration (290 mg/kg). The higher drug concentration resulted
in highly efficient microglial depletion, with 7-d treatment
eliminating ∼90% of microglia and 21-d treatment eliminating
virtually all microglia (Fig. S2).
Microglial ablation during a critical time window of
neurodegeneration development completely
blocks neurodegeneration
We treated 6-mo-old (186 d) TE4 and TEKO mice as well as their
aged matched non-tau transgenic littermates with control or
PLX3397-supplemented AIN-76A chow for 3 mo (99 d), and
collected mouse brains at 9.5 mo of age (285 d). Consistent with
our previous findings, TE4 mice treated with control chow
showed severe brain atrophy predominantly in the hippocampus, piriform/entorhinal cortex, and amygdala, accompanied by
significant dilatation of the lateral ventricle (Fig. 1). In contrast,
TEKO mice were largely protected from tissue loss and showed
preserved brain volume (Fig. 1). Strikingly, when microglia were
depleted in TE4 mice for merely 3 mo, specifically during the
stage when neurodegeneration begins and rapidly deteriorates,
neurodegeneration was virtually fully blocked, and the brain
volume of these mice remained the same as that of non-tau
transgenic mice (Fig. 1). This strongly suggests that microglia
are the driving force of neurodegeneration and disease progression in this tauopathy mouse model.
ApoE regulates neurodegeneration in P301S mice
predominantly by regulating microglia-mediated innate
immune response
As we had described previously (Shi et al., 2017), TEKO mice
consistently showed a marked reduction of brain atrophy compared with TE4 mice (Fig. 1). While there was a slight trend,
PLX3397-treated TEKO mice did not show a significantly
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increased brain volume compared with control TEKO mice
(Fig. 1). The similar protective effects of microglial depletion and
Apoe deletion on neurodegeneration suggest that apoE and microglia may function in the same axis in regulating neurodegeneration. Intriguingly, by depleting microglia, the effect of
apoE on neurodegeneration was abolished, with PLX3397treated TE4 and TEKO mice showing equal brain volumes
(Fig. 1). This suggests that the effect of apoE on neurodegeneration is predominantly mediated by its immunomodulatory property in regulating microglial functions. However,
this does not exclude the possibility that apoE directly regulates
tau pathogenesis.
ApoE deficiency leads to a higher resistance of microglia to
PLX3397-induced cell death and keeps the surviving microglia
in a homeostatic state
To confirm microglial depletion in PLX3397-treated mice, we
stained mouse brain sections with ionized calcium binding
adaptor molecule 1 (Iba1) to assess the total microglia population.
We found that PLX3397 treatment resulted in ∼100% microglial
depletion in nearly all TE4 and E4 mice throughout the brain
(Fig. 2, A and B), with only a few TE4 mice retaining a small pool
of microglia in the piriform/entorhinal cortex and even sparser
microglia in the hippocampus (Fig. 2 D). These Iba1+ microglia
almost invariably co-localized with a microglial activation
marker, cluster of differentiation 68 (CD68; Fig. 2 E), indicating
an activated status. A previous study showed that Csf1r expression is down-regulated in activated microglia in neurodegenerative conditions (Krasemann et al., 2017), suggesting that
activated microglia are less dependent on the CSF1R signaling
pathway, and therefore may be less susceptible to apoptosis
induced by blockage of CSF1R signaling. Interestingly, in addition to sparse Iba1+CD68+ microglia in the gray matter, there
were also significant CD68+Iba1− signals in the white matter,
particularly in the fimbria (Fig. 2 E), suggesting two different
types of activated microglia in the hippocampus. The retention
of CD68+ microglia in these drug-treated TE4 mice correlated
with a higher level of neurodegeneration in respective brain
regions (Fig. 2 F), suggesting a linkage between activated microglia and neurodegeneration.
Interestingly, Apoe ablation, particularly in the presence of
the tau transgene, increased microglial resistance to PLX3397induced cell death, resulting in a higher retention of Iba1+ microglia not only in the hippocampus and piriform/entorhinal
cortex, but also occasionally in other brain regions such as
thalamus (Fig. 2, A and C). However, unlike surviving microglia
in TE4 mice, the remaining microglia in TEKO mice were largely
negative for CD68 (Fig. 2 G), indicating maintenance of a homeostatic status. The enhanced survival of nonactivated microglia in Apoe-deficient mice suggests that apoE regulates CSF1R
signaling in microglia and likely affects downstream functions
such as cell survival, proliferation, and differentiation. Apoe
ablation may reprogram microglia to be less dependent on CSF1R
signaling or raise the threshold for microglial apoptosis by upregulating CSF1R expression. Therefore, microglial preservation
in TE4 and TEKO mice upon PLX3397 treatment likely followed
two distinct mechanisms. The retention of nonactivated
Journal of Experimental Medicine
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Figure 1. Microglial depletion fully rescues neurodegeneration in TE4 mice and eliminates apoE’s effect on neurodegeneration. (A) Representative
images of mouse brain sections stained with Sudan black for 9.5-mo-old TE4, TEKO, E4, and EKO mice treated with control or PLX3397-supplemented chow.
Scale bar = 1 mm for all images. (B) Quantification of brain volumes in the hippocampus and the piriform/entorhinal cortex (Ent/Piri Ctx) of the mice (TE4-Ctl:
n = 21; TE4-PLX: n = 17; TEKO-Ctl: n = 19; TEKO-PLX: n = 18; E4-Ctl: n = 12; E4-PLX: n = 6; EKO-Ctl: n = 13; EKO-PLX: n = 6). Data are expressed as means ± SEM.
One-way ANOVA with Tukey’s post hoc test (two-sided) was used for statistical analyses. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. The Sudan
black staining and brain volume quantification was performed once.

microglia in TEKO mice is likely due to an intrinsically higher
resistance to or a higher tolerance of PLX3397-induced apoptosis
by apoE-deficient microglia, whereas the CD68+ microglia retained in TE4 mice likely came from enhanced survival of microglia that had been activated before PLX3397 treatment, owing
to the accelerated disease progression in TE4 mice. The dissociation between Iba1 and CD68 signals in PLX3397-treated TEKO
mice was most prominent in the hippocampus, where >95% of
remaining Iba1+ microglia were CD68 negative, whereas in the
piriform/entorhinal cortex, a higher and more variable degree of
co-localization was observed (Fig. 2 G). The emerging CD68+
microglia in PLX3397-treated TEKO mice was most likely due to
chronic activation of the initially surviving nonactivated microglia during disease progression at a later stage. The variation
of the CD68+ microglia levels between the hippocampus and
piriform/entorhinal cortex indicates relatively independent
disease progression in these two brain regions, with the piriform/entorhinal cortex appearing to be affected earlier than the
hippocampus.
The activation status of microglia, but not the proliferation of
microglia, is associated with neurodegeneration
Interestingly, we observed no difference in the percent area
covered by Iba1 immunoreactivity between TE4 and TEKO mice
treated with the control chow (Fig. 2, A and B), despite a significant difference of brain volume between these mice. In
contrast, there was a significant reduction of CD68 immunoreactivity in control chow-treated TEKO mice compared with TE4
mice (Fig. 3, A and B). Furthermore, the amount of CD68 immunoreactivity highly correlated with the degree of brain
Shi et al.
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atrophy (Fig. 3 C). This supports the idea that the activation
status of microglia, but not their absolute number, determines
microglial neurodegenerative functions. On the other hand, we
observed no difference in the level of glial fibrillary acidic protein (GFAP)+ astrocytes in TE4 and TEKO mice treated with either
control or PLX3397-supplemented chow (Fig. S3), suggesting that
the number of GFAP+ astrocytes is not directly linked with
neurodegeneration.
Microglia are the driving force of tau pathogenesis and
mediate apoE’s effect on tau pathology
Microglial activation has been shown to promote tau phosphorylation by activating tau kinases via IL-1 signaling (Li et al.,
2003; Kitazawa et al., 2005). To understand how tau pathology develops with little to no impact of microglia and how apoE
regulates tau pathogenesis independent of its effect on microglia, we analyzed tau pathology in mouse brains. We first stained
brain sections with the AT8 antibody that recognizes the Ser202
and Thr205 epitopes of phosphorylated tau (ptau). We previously identified four types of ptau staining patterns (type1–
type4) in P301S tau transgenic mice that are associated with
progressively more advanced pathological tau/neurodegeneration stages (Shi et al., 2017). Consistent with our
previous findings, TEKO mice treated with control chow were
highly enriched with the type1 pattern, which represents the
earliest pathological tau stage, whereas TE4 mice treated with
control chow showed predominantly type3 and type4 patterns,
which are associated with advanced tau stages and neurodegeneration (Fig. 4, A and B). Remarkably, microglial depletion in TE4 mice from 6 mo of age, a time point shortly after tau
Journal of Experimental Medicine
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Figure 2. ApoE deficiency increases homeostatic microglial survival in PLX3397 treatment. (A) Representative images of Iba1 staining for 9.5-mo-old
TE4, TEKO, E4, and EKO mice treated with control (Ctl) or PLX3397-supplemented (PLX) chow. Scale bar = 1 mm for all images. (B) Quantification of Iba1covered areas in these brain sections (TE4-Ctl: n = 21; TE4-PLX: n = 17; TEKO-Ctl: n = 19; TEKO-PLX: n = 18; E4-Ctl: n = 12; E4-PLX: n = 6; EKO-Ctl: n = 13; EKOPLX: n = 6). (C) Quantification of Iba1-covered area in PLX3397-treated mice alone. (D) A representation image of a TE4 mouse that showed incomplete
microglial depletion in the brain. Scale bar = 1 mm. (E) Co-localization of Iba1 and CD68 signals in the surviving microglia in the hippocampus and entorhinal/
piriform cortex (Ent/Piri Ctx) of a TE4 mouse. Scale bar = 500 μm. (F) The presence of surviving CD68+ microglia in some PLX3397-treated TE4 mice was
associated with higher levels of neurodegeneration in the hippocampus and entorhinal/piriform cortex. (G) The surviving microglia in PLX3397-treated TEKO
mice were predominantly CD68− in the hippocampus, but showed a higher degree of co-localization with CD68 in the entorhinal/piriform cortex. Hippocampus
and piriform/entorhinal cortex share the same scale with the respective regions in E. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. The fluorescent
stainings were performed once.
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Figure 3. Activated microglia are associated with neurodegeneration. (A) Representative images of CD68 staining in the hippocampus and entorhinal/
piriform cortex (Ent/Piri Ctx) of 9.5-mo-old TE4 and TEKO mice treated with control (Ctl) or PLX3397-supplemented (PLX) chow. Scale bar = 500 μm. Images of
the same brain region share the same scale. (B) Quantification of CD68-covered area in all groups of mice (TE4-Ctl: n = 21; TE4-PLX: n = 17; TEKO-Ctl: n = 19;
TEKO-PLX: n = 18; E4-Ctl: n = 12; E4-PLX: n = 6; EKO-Ctl: n = 13; EKO-PLX: n = 6). (C) Correlation between CD68 signal and the brain volume in the hippocampus and entorhinal/piriform cortex in control TE4 and TEKO mice. Pearson correlation analysis (two-sided). Hippocampus: R2 = 0.6872, P < 0.0001;
entorhinal/piriform cortex: R2 = 0.5611, P < 0.0001. Data are expressed as means ± SEM. One-way ANOVA with Tukey’s post hoc test. **, P < 0.01; ****, P <
0.0001. The CD68 staining was performed once.

pathology onset, completely blocked the progression of pathological tau stages, resulting in almost exclusively a type1 pattern in these mice (Fig. 4 B). This result strongly indicates that
microglia are the primary driving force of ptau histopathology.
Activated microglia either directly induce tau hyperphosphorylation by activating tau kinases through IL-1 or other
signaling pathways, or trigger neurodegeneration that leads to
secondary tau hyperphosphorylation and aggregation as a
consequence of neuronal injury. Microglial depletion in TEKO
mice did not further change the ptau staining pattern as compared with TEKO control mice, as both groups showed similar
enrichment of type1 tau (Fig. 4 B). Quantification of AT8 immunoreactivity in the hippocampus revealed a significant ptau
reduction in PLX3397-treated TE4 mice compared with control
TE4 mice, with no difference noted between PLX3397-treated
and control TEKO mice (Fig. 4 C). However, we noticed that
type1 tau exhibited two sub-categories: an early-type1 stage
characterized by solely mossy fiber staining and a late-type1
stage featuring emerging neuronal cell body and neuritic
staining in addition to mossy fiber staining (Fig. 4 D). We found
that control TEKO mice demonstrated a significant shift from
the early-type1 tau toward the late subtype relative to PLX3397treated TEKO mice (Fig. 4 E), indicating a mildly accelerated
rate of disease progression. Notably, in the absence of microglia, TE4 and TEKO mice showed comparable degrees of
ptau pathology with similar ptau patterns and AT8 coverage,
suggesting that the effect of apoE on tau histopathology is
primarily mediated by apoE modulating microglial function.
Shi et al.
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We next performed biochemical analysis for these samples.
Mouse posterior cortical tissue was extracted sequentially in
reassembly buffer (RAB; salt buffer), radioimmunoprecipitation
assay buffer (RIPA; detergent buffer), and 70% formic acid (FA),
which contain soluble, less soluble, and highly insoluble proteins, respectively. Ptau and human tau levels in each fraction
were analyzed via quantitative ELISA. We found that PLX3397
treatment significantly reduced ptau levels in both TE4 and
TEKO mice (Fig. 5 A). Surprisingly, while comparable human
tau levels between groups were observed in most fractions,
there was a significant increase of insoluble tau level in
PLX3397-treated TE4 mice relative to control TE4 mice, despite
preserved brain volume in PLX3397-treated TE4 mice (Fig. 5 B).
The elevation of insoluble tau was likely a secondary effect of
PLX3397 treatment and appeared to be associated with Apoe
status, as no difference was observed between control and
PLX3397-treated TEKO mice. The concurrence of increased insoluble tau and attenuated brain atrophy suggests that formation of insoluble tau does not directly cause neurodegeneration
manifested as brain volume loss.
PLX3397 treatment in TE4 mice induces a marked elevation of
soluble apoE present in astrocytes and neurons that positively
correlates with ptau and insoluble human tau levels
Based on the protective effect of apoE deficiency on neurodegeneration, we reasoned that PLX3397 treatment may reduce
apoE levels in TE4 mice. However, we unexpectedly observed a four
to fivefold increase of soluble apoE levels in PLX3397- treatedTE4
Journal of Experimental Medicine
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Figure 4. Microglia drive tau pathogenesis and mediate apoE’s effect on tau pathogenesis. (A) Representative images of the four major ptau staining
patterns in 9.5-mo-old TE4 and TEKO mice. Scale bar = 500 μm for all images. (B) Distribution of the four ptau staining patterns in 9.5-mo-old TE4 and TEKO
mice treated with control (Ctl) or PLX3397-supplemented (PLX) chow (TE4-Ctl: n = 21; TE4-PLX: n = 17; TEKO-Ctl: n = 19; TEKO-PLX: n = 18). Fisher’s exact test,
two-sided (all groups: P = 2.2 × 104; TE4-Ctl vs. TE4-PLX: P = 4.1 × 104; TE4-Ctl vs. TEKO-Ctl: P = 4.1 × 104). (C) Quantification of ptau (AT8)-covered area in the
hippocampus of these mice. (D) Representative images of early-type1 and late-type1 ptau staining patterns within the type1 category (same image used for
type1 and type1-early in A and D, respectively). Scale bar = 500 μm for both images. (E) Distribution of early-type1 and late-type1 ptau patterns in TE4 and
TEKO mice harboring the type1 ptau staining pattern (TE4-Ctl: n = 6; TE4-PLX: n = 15; TEKO-Ctl: n = 11; TEKO-PLX: n = 11). Fisher’s exact test, two-sided (all
groups: P = 0.0097; TEKO-Ctl vs. TEKO-PLX: P = 0.0089). Data are expressed as means ± SEM. One-way ANOVA with Tukey’s post hoc test (two-sided). **, P <
0.01; ***, P < 0.001. The AT8 staining was performed once.

and E4 mice relative to their control chow-treated counterparts,
with TE4-PLX mice showing an even higher level of apoE compared
to E4-PLX mice (Fig. 5 C). Because the apoE ELISA assay we used is
incompatible with RIPA and FA fractions, we were only able to
measure apoE levels in the RAB fraction. To exclude the
possibility that we were detecting only a specific pool of apoE
by ELISA using the monoclonal apoE antibodies and to assess
apoE levels in other fractions, we performed immunoblotting
for both the RAB and RIPA fractions using a polyclonal apoE
antibody. We confirmed a marked elevation of apoE levels
predominantly in the RAB fraction in PLX3397-treated TE4
and E4 mice as compared with control mice (Fig. 5 D), indicating a primarily soluble state of elevated apoE.
To understand where the elevated apoE came from, we costained apoE with various cell type markers in brain sections.
Compared with control TE4 and E4 mice, there was a strong
increase in the intensity of apoE signal that largely co-localized
with GFAP+ astrocytes in both PLX3397-treated TE4 and E4 mice
(Fig. 6, A–F). Diffuse apoE staining was also enhanced (Fig. 6,
A–D), and no apoE signal was observed in oligodendrocytes
(Fig. 6 G). Intriguingly, in PLX3397-treated TE4 mice, apoE
staining was also present in cells of neuronal morphology, the
Shi et al.
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signal of which was particularly strong in the dentate gyrus
(Fig. 6, A and H–J), CA3 of the hippocampus, and the piriform/
entorhinal cortex (Fig. S4). This type of signal was barely observed in PLX3397-treated E4 mice except weakly in the piriform/entorhinal cortex (Fig. S4, A and B), and was not at all
present in control TE4 or E4 mice. This apoE staining pattern
was verified by five different monoclonal and polyclonal apoE
antibodies (data not shown) and by no apoE staining in PLX3397treated or control TEKO/EKO mice (Fig. 6 E and Fig. S4, A and B).
The apoE+ neuronal shaped cells did not co-localize with neuronal nuclei (NeuN), a marker for mature neurons (Fig. 6 I and
Fig. S4 D), but partially co-localized with ptau-positive neurons
(Fig. 6 J), indicating that they very likely represent a subset of
neurons. They may be neuronal precursor cells or immature
neurons that have been reported to express CSF1R (Nandi et al.,
2012), or they may be CSF1R-expressing mature neurons (Luo
et al., 2013) that have switched from being NeuN+ to NeuN− via
transcriptional reprogramming in response to intracellular apoE
buildup (either due to de novo apoE synthesis or apoE uptake
and accumulation). The number of apoE+ neurons in PLX3397treated TE4 mice varied across samples and appeared to correlate with the amount of ptau signal in individual samples,
Journal of Experimental Medicine
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Figure 5. PLX3397 treatment in TE4 mice results in a sharp elevation of soluble apoE level that correlates with higher ptau and insoluble human tau
levels. (A and B) ELISA results showing concentrations of ptau and human tau in RAB, RIPA, and FA fractions, respectively, for 9.5-mo-old TE4 and TEKO mice
treated with control (Ctl) or PLX3397-supplemented (PLX) chow (TE4-Ctl: n = 21; TE4-PLX: n = 17; TEKO-Ctl: n = 19; TEKO-PLX: n = 18). (C) Human apoE level in
the RAB fraction for 9.5-mo-old TE4 and E4 mice treated with control or PLX-supplemented chow (TE4-Ctl: n = 21; TE4-PLX: n = 17; E4-Ctl: n = 12; E4-PLX: n = 6).
(D) Western blot probing for human apoE in the RAB and RIPA fractions for 9.5-mo-old TE4 and E4 mice treated with control or PLX3397-supplemented chow
(n = 3 per group). (E) Correlation of RAB-soluble apoE level with soluble and insoluble human tau levels, respectively. Pearson correlation analysis (two-sided).
RAB apoE vs. FA tau: R2 = 0.6240, P = 0.0002; RAB apoE vs. RAB tau: R2 = 0.1581, P = 0.1. (F) Correlation of RAB-soluble apoE level with ptau levels in the RAB,
RIPA, and FA fractions, respectively, in PLX3397-treated TE4 mice. Pearson correlation analysis (two-sided). RAB apoE vs. RAB ptau: R2 = 0.8039, P < 0.0001;
RAB apoE vs. RIPA ptau: R2 = 0.7312, P < 0.0001; RAB apoE vs. FA ptau: R2 = 0.5369, P = 0.0008. Data are expressed as means ± SEM. One-way ANOVA with
Tukey’s post hoc test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. All ELISAs were repeated twice.
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Figure 6. Elevated apoE in PLX3397-treated TE4 mice is present in astrocytes and a subset of NeuN− neurons. (A–E) Representative images of apoE
(green, first column), GFAP (red, second column), and merged apoE/GFAP (third column) staining in the hippocampus of 9.5-mo-old TE4-PLX, TE4-Ctl, E4-PLX,
E4-Ctl, and TEKO-PLX mice, respectively. Scale bar = 50 μm for all images in the three columns. Far left column: zoom-in of the selected area in respective apoE
staining images. Scale bar = 10 μm. (F) Co-localization of apoE with GFAP+ astrocytes in TE4-PLX mouse hippocampus. Scale bar = 10 μm. (G) Non-colocalization between apoE and CNPase+ oligodendrocytes in TE4-PLX mouse hippocampus. Scale bar = 10 μm. (H) Non-co-localization between apoE and
NeuN in TE4-PLX mouse dentate gyrus. Scale bar = 50 μm. (I) Zoom-in of the selected area in H. Scale bar = 10 μm. (J) Partial co-localization of apoE with AT8+
neurons in TE4-PLX mouse dentate gyrus. Arrowheads point to some co-localized neurons. Scale bar = 10 μm. For F–J, the third column is a merged image of
the first two columns. ApoE staining was repeated seven times using different antibodies.

suggesting that tau pathology likely increases the sensitivity of
these neurons to CSF1R signaling and promotes neuronal apoE
buildup upon CSF1R blockage. Overall, while elevated apoE in
PLX3397-treated E4 and TE4 mice primarily came from astrocytes, the additional elevation of apoE in TE4-PLX mice over
E4-PLX mice appeared to be due to an increased apoE level in
subsets of neurons.
Interestingly, we found that the level of RAB-soluble apoE
correlated with a lower level of soluble tau and a higher level of
insoluble tau in PLX3397-treated TE4 mice (Fig. 5 E). In addition,
there was a strong positive correlation between apoE level and
ptau levels in all three fractions (Fig. 5 F). These correlations
remained significant even after excluding the samples that
showed incomplete microglial depletion (data not shown), indicating that apoE derived from astrocytes and likely neurons
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may directly regulate tau pathogenesis by promoting ptau generation and insoluble tau formation independent of the impact
of microglia. However, this direct effect of apoE on tau pathogenesis by itself was insufficient to impact neurodegeneration.
The neuroprotective effect of PLX3397 is unlikely due to its
direct impact on neurons
Previous studies report CSF1R expression in small subsets of
neurons under normal conditions, and the expression goes up
with neuronal injury (Wang et al., 1999; Luo et al., 2013).
Therefore, it is possible that PLX3397 protects against neurodegeneration via a direct effect on neurons. However, neuronal
CSF1R signaling has been shown to promote neuronal survival
(Wang et al., 1999; Nandi et al., 2012; Luo et al., 2013; Chitu et al.,
2016). Therefore, assuming PLX3397 indeed affects neuronal
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Figure 7. PLX3397 does not have a direct
protective effect on neurons. (A and B) Primary hippocampal neurons derived from E17
apoE4 KI mouse embryos were infected with
AAV2/8-Syn-P301S tau, and cultured at a density
of 40,000 or 100,000 cells/well, respectively, in
24-well plates for 8 d in AraC-supplemented
medium. The neurons were treated with either
DMSO or 8.5 μM PLX3397 at plating. Representative images of neurons stained with MAP2. Scale
bar = 50 μm for all images. (C and D) Quantification of neuron cell numbers in each imaging field.
For 40,000 cells/well: n = 8 replicates per group;
for 10,000 cells/well: n = 3 replicates per group.
Data are expressed as means ± SEM. Unpaired
two-tailed Student’s t test. *, P < 0.05. This experiment was performed once.

function, it would be likely to have a detrimental rather than
protective effect on neurons.
To understand whether and how PLX3397 might directly
impact neurons, we cultured hippocampal neurons derived from
apoE4 knockin (KI) mice in cytarabine (AraC)-supplemented
medium and infected the neurons with adeno-associated virus
(AAV)2/8-Syn-P301S Tau. We treated the neurons with either
DMSO or 8.5 μM PLX3397 (comparable to PLX3397 concentration in drug-treated mouse brains) at plating and maintained the
culture for 8 d. No astrocytes or microglia were detected by the
end of the experiment. At a lower plating density (40,000 cells/
well), PLX3397 did not affect neuronal cell number, but mildly
inhibited neurite outgrowth (Fig. 7, A and B). At a higher density
(100,000 cells/well), the inhibition of neurite outgrowth by
PLX3397 became highly prominent, and a mild reduction of
neuron number was observed (Fig. 7, C and D). These results
were consistent with previous studies showing that CSF1R signaling promotes neuronal survival and neuronal differentiation
(Wang et al., 1999; Nandi et al., 2012; Luo et al., 2013; Chitu et al.,
2016), suggesting that the neuroprotective effect of PLX3397 in
TE4 mice was likely not due to a direct effect of PLX3397 on
neurons.
Effects of PLX3397 treatment on blood cell phenotyping
To understand whether PLX3397 affects blood cell populations
other than microglia in the brain, we performed complete blood
count (CBC) for mouse whole blood as well as flow cytometry for
white blood cells in all groups of mice. CBC results showed that
PLX3397 treatment significantly reduced the number of RBCs
(RBC and hematocrit %) and hemoglobin levels (hemoglobin and
mean corpuscular hemoglobin concentration), while increasing
the size of RBCs (mean corpuscular volume) in all groups (Fig. 8
A). The number of platelets was also reduced (Fig. 8 B). Interestingly, PLX3397 treatment reduced the total number of white
blood cells in E4 and TE4 mice, but not in EKO and TEKO mice
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(Fig. 8 C), suggesting an apoE-dependent effect on white blood
cells under PLX3397 treatment. Detailed analysis by flow cytometry (gating strategy summarized in Fig. S5) revealed that
PLX3397 treatment reduced or showed a trend of reducing the
frequency of dendritic cells (DCs), natural killer (NK) cells, and
Ly6C− monocytes in all groups of mice (Fig. 8, D–F). PLX3397
preferentially targeted Ly6C− monocytes over Ly6C+ monocytes,
including Ly6Chi and Ly6Clo monocytes (Fig. 8 F). We found that
in control chow-treated mice, Ly6C+ monocytes expressed a
significantly higher level of CSF1R (CD115) compared with Ly6C−
monocytes (Fig. 8 G), suggesting a higher tolerance to CSF1R
inhibition-induced cell death by Ly6C+ monocytes. Interestingly,
PLX3397 treatment led to a notable reduction of CSF1R expression in Ly6C+ monocytes and a milder CSF1R reduction in Ly6C−
monocytes, with all surviving monocyte populations expressing
a similarly low level of CSF1R (Fig. 8 G). Therefore, while the
initial CSF1R expression level may be a key factor determining
the susceptibility of monocytes to PLX3397-induced cell death,
blockage of CSF1R signaling down-regulated CSF1R expression
in the surviving monocytes and converted them to a phenotype
that was less dependent on CSF1R signaling. No difference in
neutrophil levels was observed between groups, whereas eosinophils showed a trend of increased frequency upon PLX3397
treatment (data not shown). Interestingly, EKO and TEKO mice
showed an overall increased frequency of multiple myeloid cell
types compared with E4 and TE4 mice, suggesting that apoE
deficiency is associated with a higher proliferative capacity of
certain myeloid cells. On the other hand, there appeared to be an
overall trend of increased T cell frequency (Fig. 8 H) upon
PLX3397 treatment. This effect was most pronounced in TEKO
mice and was observed in all the T cell subpopulations, including
regulatory T cells (T reg cells; Fig. 8 I), CD4+ T cells, CD8+ T cells,
memory T cells, and NK T cells (other data not shown). In addition, there was a trend of increased B cell frequency in control
TE4 mice over other groups (Fig. 8 J). The significance of these
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Figure 8. PLX3397 treatment and apoE status regulate blood cell phenotyping. (A–C) Complete blood cell count results for the level of RBCs, hemoglobin,
platelets, and white blood cells in 9.5-mo-old mice of all genotypes treated with control (Ctl) or PLX3397-supplemented (PLX) chow (TE4-Ctl: n = 14; TE4-PLX:
n = 7; TEKO-Ctl: n = 11; TEKO-PLX: n = 10; E4-Ctl: n = 13; E4-PLX: n = 8; EKO-Ctl: n = 10; EKO-PLX: n = 7). (D–F) Flow cytometry quantification of the frequency
of DCs, NK cells, Ly6Chi, Ly6Clo, and Ly6C− monocytes, respectively (TE4-Ctl: n = 7; TE4-PLX: n = 7; TEKO-Ctl: n = 7; TEKO-PLX: n = 5; E4-Ctl: n = 11; E4-PLX: n = 8;
EKO-Ctl: n = 5; EKO-PLX: n = 5). (G) Median fluorescence intensity (MFI) of CSF1R (CD115) in Ly6Chi, Ly6Clo, and Ly6C− monocytes in all groups of mice (two-way
ANOVA with Sidak’s post hoc test). (H–J) Population frequencies for T cells, T reg cells, and B cells, respectively. Data are expressed as means ± SEM. One-way
ANOVA with Tukey’s post hoc test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. HCT, hematocrit; HGB, hemoglobin; MCHC, mean corpuscular
hemoglobin concentration; MCV, mean corpuscular volume . The CBC and flow cytometry experiments for blood cell phenotyping were performed >10 times.

blood cell changes and their potential influence on brain pathogenesis and neurodegeneration are still unclear, and need to be
further addressed in future studies.

Discussion
AD and many other neurodegenerative diseases are known as
proteopathies characterized by accumulation of misfolded and
aggregated proteins. For decades, research and drug development in the AD field have largely focused on the two pathological
protein hallmarks of AD, amyloid-β and tau pathology. Given a
high correlation between tau pathology and AD clinical readouts
(Arriagada et al., 1992; Josephs et al., 2008), pathological tauinduced cell-autonomous neurotoxicity was believed to play a
key role in driving neurodegeneration. It was not until recently
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that the role of brain innate immunity in AD and tauopathy
pathogenesis became increasingly recognized. While it is widely
acknowledged that chronic innate immune activation in the
brain can cause neuronal loss, the interaction between innate
immunity and tau pathology and their respective contributions
to neurodegeneration are not well understood. This is largely
due to an intertwined relationship between tau pathogenesis
and innate immunity, making it difficult to separate the two
effects. With complete microglial depletion, we were able to
assess the impact of microglia on tau pathogenesis, as well as
the effect of tau pathology on neurodegeneration, independent
of the influence of microglia-mediated inflammation on
neurodegeneration.
Here, we demonstrated that microglia served as the driving
force of neurodegeneration in a mouse model of tauopathy.
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Depletion of microglia in TE4 mice upon neurodegeneration
onset fully blocked development of brain atrophy. Importantly,
in the absence of microglia, progression of ptau pathology was
halted, indicating that ptau pathogenesis is also predominantly
driven by microglia-mediated inflammation. It is unclear
whether the rescue of neurodegeneration in the absence of
microglia resulted from a direct attenuation of inflammationinduced neuronal loss or was an indirect result of blocked
ptau pathology due to lack of tau-induced neurotoxicity. While
we cannot exclude the role of tau pathology in inducing neurodegeneration, our results suggest that ptau pathology progresses very slowly in the absence of microglia. Whether tau
pathology could progress to an advanced stage within a normal
lifespan independent of microglia to affect neurodegeneration is
uncertain. In addition, PLX3397-treated TE4 mice showed a
preserved brain volume despite harboring an increased level of
insoluble tau compared with control TE4 mice, suggesting that
certain forms of pathological tau do not directly cause neuronal
death. This is consistent with previous reports that tau tangles
are off the pathway of acute neuronal death (de Calignon et al.,
2009, 2010; Kuchibhotla et al., 2014). Therefore, microglial activation, rather than pathological tau-induced neurotoxicity, is
likely the key factor dictating disease progression in this model.
We did not observe a difference of GFAP immunoreactivity
between PLX3397-treated and control groups, suggesting that
GFAP+ astrocytes do not directly regulate neurodegeneration.
However, it is possible that astrocytes crosstalk with microglia
to influence neurodegeneration. Regardless, the fact that microglial depletion is sufficient to block tau pathology and neurodegeneration suggests that microglia play a key role in
mediating neurodegeneration.
Interestingly, a previous study showed that a mild microglia
reduction (∼30%) by PLX3397 treatment did not change tau
burden or cortical atrophy in a tauopathy mouse model (Bennett
et al., 2018). We found that the retention of even a small population of activated microglia was associated with more neurodegeneration compared with complete microglial eradication,
suggesting a potent role of activated microglia in regulating
neurodegeneration and the requirement of depletion of the vast
majority of microglia in order to reveal their effects on neurodegeneration. We surprisingly found a mouse chow- and sexdependent effect on the efficiency of microglial depletion,
revealing the complexity of immune regulation that can be easily
neglected. While the effects appeared to be due to differences in
plasma PLX3397 levels, whether plasma PLX3397 concentration is
affected by food digestion/absorption, drug catabolism regulated
by blood cell composition that is potentially affected by chow type
or sex, or other factors is unknown. We found that the chow
formulas indeed could affect blood cell phenotypes. For instance,
Purina 5053 resulted in an increase of the neutrophil population
and a concomitant down-regulation of the lymphocyte population
compared with AIN-76A (data not shown). These variables should
be taken into consideration in future studies.
We identified a critical difference between microglial proliferation and microglial activation, the concepts of which have
not always been clear in previous studies. Control TEKO mice
showed no difference and even a trend of higher level of Iba1+
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microglia compared with control TE4 mice, despite a marked
rescue of brain volume loss in TEKO mice. In contrast, the level
of CD68+-activated microglia was notably lower in control TEKO
mice and highly correlated with the level of neurodegeneration,
suggesting that the activation status of microglia, rather than the
absolute number of microglia, is functionally associated with
neurodegeneration. Microglial proliferation represents one aspect of microglial biology upon stimulation, but is not necessarily linked with transcriptional programming that converts
microglia to an activated neurodegenerative phenotype. ApoE
deficiency does not block the proliferating capacity of microglia.
In fact, it appears to increase microglial numbers under certain
stimulating conditions, such as mild neurodegeneration as was
observed in control TEKO mice, or LPS stimulation as was reported in previous literature (Zhu et al., 2012). We also observed
a larger population of certain blood myeloid cells in EKO and
TEKO mice relative to TE4 and E4 mice. In addition, TEKO and
EKO mice presented a higher resistance to PLX3397-induced
microglial cell death relative to TE4 and E4 mice, with preservation of predominantly nonactivated microglia. This evidence
suggests that apoE deficiency promotes the proliferation and
survival of certain myeloid cell lineages but may interfere with
their functional maturation. In the brain, apoE deficiency prevents microglia from acquiring an activated status featuring a
neurodegenerative phenotype that promotes neural injury
(Krasemann et al., 2017). How apoE controls the survival, proliferation, and activation of microglia is unclear. One possibility
is through regulating CSF1R signaling. However, detailed studies
are needed in the future to address this question.
We previously uncovered a significant role of apoE in regulating neurodegeneration in the setting of tauopathy. We proposed
two major mechanisms through which apoE modulates neurodegeneration: 1) apoE regulates tau pathogenesis (i.e., progression
of ptau stages); and 2) apoE regulates glia-mediated innate immunity. However, the respective contribution of the two mechanisms to apoE’s effect on neurodegeneration was unclear, given
that the effect of apoE on tau pathogenesis was obscured by effects
of apoE on innate immunity. Our current experimental scheme
allows simultaneous assessment of the two aspects. We found that
the effect of apoE on neurodegeneration was eliminated in the
absence of microglia, suggesting a central role of microglia in
mediating apoE’s effect on neurodegeneration. Importantly, effects of apoE on ptau stage progression and ptau immunoreactivity were also abolished upon microglial depletion, suggesting
that the effect of apoE on tau pathogenesis was primarily driven
by the effect of apoE on microglial function, and there was no
direct effect of apoE on tau histopathology in the absence of microglia. This supports the notion that the effect of apoE on neurodegeneration in the tauopathy model predominantly results
from apoE regulating microglial function.
It is possible that the lack of apoE’s effect on tau pathology
in PLX3397-treated TE4 and TEKO mice was complicated by
the significantly higher level of retained microglia in TEKO
mice relative to TE4 mice. These excessive microglia in TEKO
mice, although mostly being CD68− that were not associated
with neuronal loss, may still be able to affect tau pathogenesis,
for instance, by producing factors to induce tau phosphorylation.
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To assess the effect of apoE on tau pathogenesis completely independent of the impact of microglia, we analyzed the level of
apoE, tau, and ptau only in PLX3397-treated TE4 mice that
showed complete elimination of microglia. Interestingly, we
found a significant positive correlation of salt-soluble brain apoE
levels with both ptau and insoluble tau levels in these mice,
suggesting a potential direct role of apoE present in astrocytes
and neurons in promoting ptau and insoluble tau formation.
However, this effect of apoE on pathological tau generation did
not contribute to brain volume loss and therefore did not significantly account for apoE’s effect on neurodegeneration.
Our previous finding that apoE deficiency strongly protects
against neurodegeneration suggests that lowering apoE levels
may be beneficial. Here, we surprisingly found a marked elevation of apoE in both astrocytes and neurons in TE4 mice upon
PLX3397 treatment. The elevated apoE level in PLX3397-treated
TE4 mice may be related to the higher insoluble tau level in
these mice, given the correlation between apoE and insoluble
tau levels. However, in contrast to control TE4 mice that showed
severe neurodegeneration, PLX3397-treated TE4 mice showed
full rescue of brain volume despite a higher apoE level. This
result illustrates a critical concept that the absolute amount of
apoE is not the only key to neurodegeneration. The effect
of apoE on neurodegeneration is dependent on the presence of
microglia. How does apoE function through microglia to induce
neurodegeneration? On the one hand, microglia-derived apoE
cell-autonomously regulates the acquisition of the neurodegenerative phenotype by microglia that leads to neural injury. It is
possible that the source and location of apoE, in addition to the
quantity of apoE, matter for neurodegeneration. ApoE present in
astrocytes and neurons may regulate ptau and insoluble tau
formation that is not associated with acute neuronal loss;
whereas microglia-derived apoE controls neurodegenerative
microglial activation and functions, and therefore may be essential for neurodegeneration. On the other hand, apoE may
serve as an opsonin coating the surface of injured or dead neurons, and recruit activated microglia via an apoE–TREM2 interaction to promote neuronal phagoptosis by microglia (Shi and
Holtzman, 2018), therefore exacerbating neurodegeneration.
Neuroinflammation in AD is primarily driven by microglia
and astrocytes. However, it’s likely that blood-circulating immune cells crosstalk with central nervous system glia cells, for
instance, via cytokine exchange, to influence disease pathogenesis. Emerging evidence that gut microbiota regulate microglial maturation and function (Erny et al., 2015; Thion et al.,
2018) supports this possibility. Previous literature reported inconsistent results regarding the effect of PLX3397 on blood
monocytes (Chitu et al., 2012; Sluijter et al., 2014), and detailed
studies of PLX3397’s impact on other blood cell types are rare.
Here, we performed blood cell phenotyping for a full panel of
major blood cell types to assess the effect of PLX3397 treatment,
apoE genotype, and disease status on blood cell composition. We
found that at a dose of 400 mg/kg chow, PLX3397 treatment had
a significant impact on the myeloid-megakaryocyte-erythroid
cell lineages, leading to a reduction of RBCs, platelets, DCs, and
Ly6C− monocytes. NK cells showed a similar reduction despite
being a lymphoid lineage. The enlarged cell body of erythrocytes
Shi et al.
APOE-dependent neurodegeneration is driven by microglia

indicates a slowing of DNA synthesis that prevents normal cell
division (Hesdorffer and Longo, 2015). This suggests that
PLX3397 may prohibit the proliferation of committed precursors
of the affected cells. Granulocytes showed either an opposite
pattern or no change, suggesting a relatively independent or
compensatory regulation mechanism. Corresponding to an
overall reduction of myeloid cells, PLX3397 increased the frequency of T cells, particularly in TEKO mice. The effect of apoE
on blood cell phenotyping was mainly reflected in increased
myeloid cell populations in apoE-deficient mice, which was in
line with a higher cell proliferation capacity associated with
apoE deficiency. Interestingly, B cell frequency was uniquely
elevated in control TE4 mice over other groups, suggesting a
potential link between B cell function and neurodegeneration.
However, the meaning of these blood cell changes and whether
they are functionally connected to microglia in the brain requires further investigation.
In summary, we demonstrated that microglial activation,
rather than tau-induced direct neurotoxicity, is the driving force
of neurodegeneration in the setting of tauopathy. Critically, the
progression of ptau pathology by itself is driven by microglia. In
addition, microglia are the key mediator of apoE’s effect on
neurodegeneration. Therefore, therapeutic strategies targeting
microglia may be a highly effective approach to prevent disease
progression. A deeper understanding of the neurodegenerative
microglial signature and how to specifically engineer and control microglial functions may be a key to the design and development of microglia-targeted therapies.

Materials and methods
Animals
P301S tau transgenic mice (#008169; The Jackson Laboratory)
expressing human P301S 1N4R tau driven by the PrP promoter
were backcrossed and maintained on a C57BL/6 background.
Human APOE4 KI mice (C57BL/6) were provided by P.M. Sullivan, and Apoe KO mice (C57BL/6) were purchased from The
Jackson Laboratory (#002052). P301S mice were crossed to
APOE4 KI or Apoe KO mice to generate TE4 and TEKO mice,
respectively. All animal procedures and experiments were performed under guidelines approved by the animal studies committee at Washington University School of Medicine.
PLX3397 formulation in mouse chow.
PLX3397 was provided by Plexxikon Inc. For the initial chow
characterization study, PLX3397 was formulated in either the
Purina 5053 (Lab Supply) chow or the AIN-76A (Research Diets)
chow at a concentration of 300 mg/kg chow. For the formal
study, PLX3397 was formulated in the AIN-76A (Research Diets)
chow at a concentration of 400 mg/kg chow.
PLX3397-supplemented chow characterization
Mice were fed with either AIN-76A or Purina 5053 chow supplemented with 300 mg/kg PLX3397 for 7 d. The amount of
chow consumption for each mouse was measured every 24 h
over the 7-d period, and was normalized to mouse weight to
obtain the amount of chow consumption per gram of mouse
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weight each day. This value was further converted to the
amount of drug consumption per day per gram of mouse weight
by multiplying the drug concentration and the drug incorporation rate in diet. Plasma drug concentrations and drug incorporation rate in diet were measured by Integrated Analytical
Solutions, Inc., via liquid chromatography tandem-mass
spectrometry.
Brain section staining
For AT8 histological staining, frozen brain sections were washed
three times in Tris-buffered saline (TBS) buffer followed by
incubation in 0.3% hydrogen peroxide in TBS for 10 min.
Sections were then washed and blocked with 3% milk in 0.25%
TBS-X (Triton X-100) for 0.5 h, followed by incubation at 4°C
overnight with biotinylated AT8 antibody (MN1020B; Thermo
Fisher Scientific). The next day, the slices were developed using
the VECTASTAIN Elite ABC HRP Kit (Vector Laboratories) following the manufacturer’s instructions. Stained sections were
imaged by the NanoZoomer digital pathology system, and pathology was quantified using Image J. For immunofluorescence
staining, sections were washed in TBS three times and blocked
in blocking buffer (3% BSA + 3% goat serum in 0.3% TBS-X) for
0.5 h at room temperature (RT), followed by overnight incubation at 4°C with primary antibodies in stain buffer (1% BSA + 1%
goat serum in 0.3% TBS-X). ApoE and 29,39-cyclic nucleotide 39phosphodiesterase (CNPase) staining required antigen retrieval
in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween
20, pH 6.0) at 95°C for 30 min before blocking. The next day, the
sections were washed in TBS and incubated with fluorescencelabeled secondary antibodies (Molecular Probes) for 1 h at RT.
The slices were then washed and mounted in Prolong Gold antifade mounting media (P36931; Molecular Probes). Images for
Iba1, CD68, and GFAP staining in Fig. 2, Fig. 3, and Fig. S3 were
taken using the Cytation 5 imager at 4× magnification with image stitching and quantified using Image J. Images for apoE colocalization experiments were taken with a Nikon A1Rsi Confocal Microscope at 40× magnification. Images for Iba1 staining in
the chow characterization experiments were taken by an epifluorescence microscope at 4× or 10× magnification and quantified using MetaMorph. Primary antibodies were as follows:
CD68 (MCA1957, 1:500; AbD SeroTec), GFAP (MAB3402, 1:2,000;
EMD Millipore), Iba1 (019–19741, 1:5,000; Wako), ApoE (13366S,
1:500; Cell Signaling), CNPase (836404, 1:500; BioLegend), and
NeuN (MAB377, 1:100; EMD Millipore).
Volumetric analysis
Brain volume was quantified as described (Shi et al., 2017).
Briefly, the left hemisphere of brain was sectioned coronally at
50 μm, and every sixth coronal brain section (300 μm between
sections) starting rostrally at bregma +2.1 mm to the dorsal end
of the hippocampus at bregma −3.9 mm was mounted for each
mouse. All mounted sections were stained with 0.1% Sudan
black in 70% ethanol at RT for 20 min and then washed in 70%
ethanol. The sections were finally washed in Milli-Q water and
coverslipped with Fluoromount. The stained slices were imaged
with the NanoZoomer, and areas of interest were traced and
measured in each slice using the NanoZoomer Digital Pathology
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viewer. The volume was calculated using the following formula:
volume = (sum of area) × 0.3 mm. For hippocampus and posterior lateral ventricle, quantification started from bregma −1.1
and ended at bregma −3.9. For piriform/entorhinal cortex,
quantification started at bregma −2.3 and ended at bregma −3.9.
Brain extraction
Mouse posterior cortical tissue was processed in RAB, RIPA, and
70% FA buffer sequentially. The tissue was first weighed and
homogenized using an electric pestle at 10 μl buffer/1 mg tissue
in RAB buffer (100 mM 2-(N-morpholino) ethanesulfonic acid, 1
mM EGTA, 0.5 mM MgSO4, 750 mM NaCl, 20 mM NaF, 1 mM
Na3VO4, pH 7.0, supplemented by protease inhibitors [Complete; Roche] and phosphatase inhibitors [PhosSTOP; Roche]).
After centrifugation at 50,000 ×g for 20 min, the supernatant
was taken as the RAB-soluble fraction, and the pellet was dissolved in RIPA buffer (150 mM NaCl, 50 mM Tris, 0.5% deoxycholic acid, 1% Triton X-100, 0.1% SDS, 5 mM EDTA, 20 mM
NaF, 1 mM Na3VO4, pH 8.0, supplemented by Complete and
PhosSTOP) at 10 μl buffer/1 mg tissue by sonication at a 30%
amplitude for 1 min. After centrifugation at 50,000 ×g for
20 min, the supernatant was taken as the RIPA-soluble fraction.
The pellet was sonicated in 70% FA at 10 μl buffer/1 mg tissue
using the same sonicating parameter, and centrifuged at 50,000 ×g
for 20 min. The supernatant was taken as the FA-soluble fraction.
All fractions were stored in −80°C until analyzed.
ELISA
The ELISA plates were coated with 20-μg/ml coating antibody
overnight at 4°C. The next day, the plates were washed in PBS
for five times, and mouse brain lysates were diluted in sample
buffer (human tau and ptau sample buffer: 0.25% BSA in PBS
with 300 μM Tris, pH 7.4; human apoE sample buffer: 0.5% BSA
in 0.025% PBS-Tween 20 [PBST]; both buffers were supplemented with protease inhibitors) and loaded into the plates in
duplicates. The plates were incubated at 4°C overnight. On the
third day, the plates were washed in PBS, followed by addition of
the detection antibody and incubation at 37°C for 90 min. The
plates were then washed with PBS and incubated with streptavidin-poly-horseradish peroxidase-40 for 90 min at RT. Plates
were then washed and developed with Super Slow ELISA
3,39,5,59-Tetramethylbenzidine (Sigma) and read at 650 nm. For
FA fractions, samples were neutralized with 3 M Tris buffer (pH
8.0) before loading into the plate. Tau5 (gift from L. Binder,
Northwestern University, Chicago, IL), HJ14.5 (in house antiptau antibody) and HJ15.6 (in house anti-human apoE antibody) were used as coating antibodies, and biotinylated HT7
(MN1000B; Thermo Fisher Scientific), biotinylated AT8
(MN1020B; Thermo Fisher Scientific), and biotinylated HJ15.4
(in house anti-human apoE antibody) were used as detection
antibodies for human tau, ptau, and human apoE ELISAs,
respectively.
Western blot
Samples from the RAB and RIPA fractions of mouse brain lysates
were run for Western blot using 4–12% NuPAGE (Invitrogen)
gels in 3-(N-morpholino) propanesulfonic acid buffer and
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transferred to nitrocellulose membranes. The membranes were
blocked with 5% milk in 0.125% PBS-X for 30 min at RT, followed
by incubation of primary antibodies (human apoE [ab24139;
Abcam] and α-tubulin [T5168; Sigma] overnight at 4°C. The
membranes were then washed with 0.0125% PBS-X and incubated with HRP-conjugated secondary antibodies (Santa Cruz)
for 1.5 h at RT. Membranes were then washed and developed
using the ChemiDoc MP Imaging System (Bio-Rad).
Primary neuron culture and PLX3397 treatment
Primary hippocampal neurons were obtained from E17 apoE4 KI
mouse fetuses. Hippocampi were dissected in calcium- and
magnesium-free HBSS with careful stripping of meninges. Tissue was digested in HBSS containing 0.25% trypsin (#15090046; GIBCO) and 0.3 mg/ml DNase (#DN-25; Sigma) at 37°C for
10 min, and was dissociated in HBSS containing 0.4 mg/ml
DNase using a fire-polished Pasteur glass pipette and filtered
through a 70-μm nylon mesh. Filtered material was pelleted at
1000 ×g for 5 min, washed with neurobasal medium (Neurobasal +
1× B27 + 1× penicillin/streptomycin + 1× L-glutamine) once, and
infected with AAV2/8-synapsin-P301S tau virus for 3 h on ice.
Cells were then pelleted, washed, and plated at a density of 40,000
cells/well or 100,000 cells/well in 500 μl neurobasal medium onto
24-well tissue culture plates that had been coated with 10 μg/ml
poly-L-lysine (#P2636; Sigma). At plating, 1 μM AraC was added
and replenished at day in vitro 5 to prevent glia growth. The
neurons were treated with 8.5 μM PLX3397 (dissolved in DMSO)
or DMSO at plating and maintained for 8 d. 200 μl fresh medium
containing 8.5 μM PLX3397 or DMSO was supplemented at day
in vitro 5.
Immunocytochemistry
At DIV8, neurons were fixed in Dulbecco’s PBS containing 4%
paraformaldehyde and 4% sucrose at RT for 10 min and permeabilized with 0.3% PBST for 10 min. After blocking in 0.1%
PBS-X containing 3% BSA and 3% goat serum for 30 min at RT,
cells were incubated with primary antibodies in stain buffer (1%
BSA + 1% goat serum in 0.1% PBS-X) overnight at 4°C. The next
day, cells were washed three times with 0.1% PBST and incubated in secondary antibodies for 1 h at RT. Cells were then
washed three times in 0.1% PBST and mounted in Prolong Gold
antifade mounting media (P36931; Molecular Probes). Images
were taken using the Cytation 5 imager at 4× magnification
using a scheme covering ∼70% of the total area of a well with
image stitching for quantification. Representative images were
taken at 10× magnification. Image J was used for quantification
of neuron number. Primary antibodies were as follows: MAP2
(AB5543, 1:4,000; EMD Millipore), GFAP (MAB3402, 1:2,000;
EMD Millipore), ALDH1L1 (ab190298, 1:400; Abcam), and Iba1
(019–19741, 1:5,000; Wako).
Blood cell phenotyping
Mouse blood was collected via cardiac puncture from anaesthetized mice into heparin-rinsed tubes. 60 μl of the whole blood
of each animal was immediately sent to Washington University
Division of Comparative Medicine Research Animal Diagnostic
Laboratory for CBC in a double-blinded manner. The rest of the
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blood was first subjected to RBC lysis using the Pharm Lyse
buffer (555899; BD Biosciences) following the manufacturer’s
instructions. The remaining white blood cells were washed with
PBS and stained with a fixable live/dead cell staining dye
(L23102; Thermo Fisher Scientific) on ice for 30 min. The cells
were then spun down and washed twice with stain buffer
(554656; BD Biosciences), followed by incubation in stain buffer
supplemented with mouse Fcγ receptor block reagent (553141;
BD Biosciences) on ice for 15 min. A master mix of all the fluorescently tagged antibodies for cell surface markers was created
by diluting the antibodies in the FcγR block–containing stain
buffer supplemented with the brilliant stain buffer (563794; BD
Biosciences). The master mix was then equally distributed to
each individual blood sample. The cells were stained on ice for
30 min. After incubation, the cells were washed twice with stain
buffer and fixed in the cytofix buffer (554655; BD Biosciences)
on ice for 10 min. After fixation, the cells were spun down,
resuspended in stain buffer, and run through flow cytometry
using a BD LSRFortessa X-20 cell analyzer. The AbC Anti-Rat/
Hamster Bead Kit (A10389; Thermo Fisher Scientific), AbC AntiMouse Bead Kit (A10344; Thermo Fisher Scientific), and ArC
Amine Reactive Compensation Bead Kit (A10346; Thermo Fisher
Scientific) were used for setting flow cytometry compensation.
Each channel was assigned a fluorescence minus one control to
set the threshold for the positive population. Around 90% of
samples were collected of 50,000 cells in the CD45+ gate, and the
remaining 10% of samples were collected of 100,000 cells in the
CD45+ gate. Data analysis and figure generation were performed
using FlowJo v10. Antibodies used for flow cytometry are as
follows: BUV395 rat anti-mouse CD45 (clone 30-F11, #564279; BD
Biosciences), APC-Cy7 rat anti-CD11b (clone M1/70, #557657; BD
Biosciences), BV605 hamster anti-mouse CD11c (clone N418,
#744179; BD Biosciences), BV650 rat anti-mouse I-A/I-E (clone
M5/114.15.2, #563415; BD Biosciences), BV786 rat anti-mouse
Siglec-F (clone E50-2440, #740956; BD Biosciences), Alexa
Fluor 700 rat anti-mouse Ly-6G (clone 1A8, #561236; BD Biosciences), PerCP-Cy5.5 rat anti-mouse Ly-6C (clone AL-21,
#560525; BD Biosciences), BV711 rat anti-mouse CD19 (clone 1D3,
#563157; BD Biosciences), Alexa Fluor 647 rat anti-mouse CD25
(clone 7D4, #563598; BD Biosciences), BUV737 rat anti-mouse
CD3 Molecular Complex (clone 17A2, #564380; BD Biosciences),
PE-Cy7 rat anti-mouse CD4 (clone RM4-5, #552775; BD Biosciences), FITC rat anti-mouse CD8a (clone 53-6.7, #553030; BD
Biosciences), PE mouse anti-mouse NK-1.1 (clone PK136, #557391;
BD Biosciences), Super Bright 436 rat anti-mouse CD115 (c-fms,
clone AFS98; eBioscience, #62-1152-82; Invitrogen), and PE-Cy5
rat anti-mouse CD44 (clone IM7, #553135; BD Biosciences).
Statistical analysis
Unless explicitly stated, all data were shown as means ± SEM.
Differences between groups were evaluated by one-way ANOVA
tests with post hoc Tukey’s multiple comparisons tests. GraphPad
Prism version 8 for Windows (GraphPad Software) was used for
these analyses and creation of the plots. For statistical analysis of
the ptau staining pattern distribution, two-sided Fisher’s exact
tests were performed using the “fisher.test” function in R version
3.5.2 (The R Foundation for Statistical Computing).
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Online supplemental material
Fig. S1 shows that microglial depletion efficiency is affected by
both sex and chow formula and correlates with plasma drug
concentration. Fig. S2 shows high efficiency of microglial depletion by PLX3397 supplemented in the AIN-76A chow at a 400mg/kg dose. Fig. S3 shows no difference of GFAP+ astrocytes in
PLX3397-treated or control TE4 and TEKO mice, or in their nontau transgenic counterparts. Fig. S4 shows elevated apoE in astrocytes and NeuN− neurons in the piriform/entorhinal cortex
of PLX3397-treated TE4 and E4 mice compared with control TE4
and E4 mice. Fig. S5 shows the gating strategy for isolating
different blood cell types in flow cytometry.
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Supplemental material
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Figure S1. Mouse sex and chow formula impact the efficiency of microglial depletion by PLX3397. (A) Iba1 staining images for 3–4-mo-old female or
male TE4 mice treated with 300 mg/kg PLX3397 supplemented in either Purina-5053 or AIN-76A diet for 7 d (n = 2–3 mice per group). Scale bar = 500 μm for all
images. (B) Quantification of Iba1-covered area in the hippocampus. (C and D) Effects of chow formula and sex on serum PLX3397 levels in relation to
microglial depletion rate. Data are expressed as means ± SEM. One-way ANOVA with Tukey’s post hoc test. *, P < 0.05; **, P < 0.01. The experiments in A and B
were repeated three times.
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Figure S2. PLX3397 supplemented in the AIN-76A diet at 400 mg/kg chow depletes microglia with high efficiency. (A) Iba1 staining images for 5–6-moold male E4 mice treated with 400 mg/kg PLX3397 supplemented in the AIN-76A diet for 7 or 21 d (n = 2–3 mice per group). Scale bar = 200 μm for all images.
(B) Quantification of Iba1-covered area in the hippocampus. Data are expressed as means ± SEM. One-way ANOVA with Tukey’s post hoc test. ****, P <
0.0001. This characterization experiment was performed once.

Figure S3. PLX3397 treatment does not affect GFAP+ astrocytes. (A) Representative images of GFAP staining for 9.5-mo-old TE4 and TEKO mice treated
with control (Ctx) or PLX3397-supplemented (PLX) chow. Scale bar = 500 μm for all images. (B) Quantification of GFAP-covered area in the hippocampus of all
mice (TE4-Ctl: n = 21; TE4-PLX: n = 17; TEKO-Ctl: n = 19; TEKO-PLX: n = 18; E4-Ctl: n = 12; E4-PLX: n = 6; EKO-Ctl: n = 13; EKO-PLX: n = 6). Data are expressed as
means ± SEM. One-way ANOVA with Tukey’s post hoc test. The GFAP staining was performed once.
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Figure S4. ApoE is elevated in astrocytes and neurons in the piriform/entorhinal cortex of PLX3397-treated TE4 and E4 mice. (A) Representative
images of apoE staining in the piriform/entorhinal cortex of 9.5-mo-old TE4-PLX, TE4-Ctl, E4-PLX, E4-Ctl, and TEKO-PLX mice, respectively. Scale bar = 50 μm
for all images. (B) Zoom-in of the selected area in A. Scale bar = 10 μm for all images. (C) Co-localization of apoE with GFAP+ astrocytes in the piriform/
entorhinal cortex of TE4-PLX mouse. Scale bar = 10 μm. (D) Non-co-localization between apoE and NeuN in the piriform/entorhinal cortex of TE4-PLX mouse.
Scale bar = 10 μm. ApoE staining was repeated seven times using different antibodies.
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Figure S5. Gating strategies for isolating blood cell types using flow cytometry. Blood cells were sequentially gated through total cells, single cells, viable
cells, and CD45+ cells. From the CD45+ gate, DCs were isolated as the MHC2+CD11c+ population. From the non-DC gate, B cells were isolated as the
MHC2+CD19+ population. From the non-B cell gate, neutrophils were isolated as the SSChighLy6G+ population. From the nonneutrophil gate, NK1.1+ cells were
isolated and further divided into CD3+ NK T cells and CD3− NK cells. The NK1.1− gate was further separated into CD11b+ and CD11b− gates. From the CD11b+
gate, eosinophils were isolated as the SSChighSiglecF+ population. From the noneosinophil gate, monocytes were isolated as the CD115+ population, which was
further divided into Ly6Chi, Ly6Clo, and Ly6C− populations. From the CD11b− gate, T cells were isolated as the CD3+ population, which was further separated
into CD4+ and CD8+ T cells, or CD44+ memory T cells. From the CD4+ T cell gate, T reg cells were isolated as the CD25+ population. SSC-A, side scatter area;
FSC-A, forward scatter area; SSC-H, side scatter height.
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